Velikyan I
Pharmaceuticals (Basel, Switzerland) 13 (3) - [2020-03-05; online 2020-03-05]
The role of nuclear medicine in the management of oncological patients has expanded during last two decades. The number of radiopharmaceuticals contributing to the realization of theranostics/radiotheranostics in the context of personalized medicine is increasing. This review is focused on the examples of targeted (radio)pharmaceuticals for the imaging and therapy of neuroendocrine neoplasms (NENs), prostate cancer, and breast cancer. These examples strongly demonstrate the tendency of nuclear medicine development towards personalized medicine.
PubMed 32151049
DOI 10.3390/ph13030039
Crossref 10.3390/ph13030039
pmc: PMC7151671
pii: ph13030039